<div id="readability-page-1"><pre>      Overview      * Retractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last year     * Operating loss for Q3 2025 reduced to $3.7 mln from $5.1 mln last year     * Company reports Q3 net income of $371 thousand, aided by $2.4 mln unrealized gains       Outlook      * Tariffs expected to continue impacting costs in future periods     * Uncertainty remains regarding timing of future international orders       Result Drivers      * TARIFF IMPACT - Co says tariffs continue to materially affect costs, spending $2.3 mln on tariffs in first nine months of 2025     * PRODUCT MIX - Higher domestic selling prices due to shift in product mix, with decreased EasyPoint needle sales     * INTERNATIONAL SALES - International revenues increased 25% in Q3, but average selling price declined due to product discounts       Key Details     Metric    Beat/Mis  Actual    Consensu            s                   s                                Estimate    Q3 Sales            $10.10                      mln  Q3                  -$3.70  Operatin            mln  g Income     Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .  (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.) </pre></div>

Retractable技术

<p>Retractable Technologies 2025 年第三季度的销售额略微下降至 1010 万美元，较去年 1030 万美元有所减少。运营亏损减少至 370 万美元，较 510 万美元有所改善。公司报告净收入为 37.1 万美元，得益于 240 万美元的未实现收益。关税继续影响成本，2025 年前九个月在关税上的支出为 230 万美元。国际收入在第三季度增长了 25%，但由于产品折扣，平均售价下降</p>

医疗器械公司 Retractable 的第三季度销售额下滑